Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
Other Sizes |
|
Purity: ≥98%
Oxaliplatin (Eloxatin; L-OHP; JM83; RP54780; SR96669), an anticancer drug used for treating colorectal cancer, is an organoplatinum complex (1,2-diaminocyclohexane (DACH) and with an oxalate ligand), acnting by inhibiting DNA synthesis by forming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. As a leaving group, an oxalate ligand and DACH form a complex with the platinum atom of oxaliplatin. Once the labile oxalate ligand has left the group, active oxaliplatin derivatives, like monoaquo and diaquo DACH platinum, alkylate macromolecules to form inter- and intra-strand platinum-DNA crosslinks. These crosslinks inhibit DNA replication and transcription and cause non-specific cytotoxicity that is specific to the cell cycle.
Targets |
DNA synthesis
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Cell Assay |
The sulforhodamine-B microculture colorimetrie assay is used to conduct the cytotoxicity investigations. The sulforhodamine-B test is typically conducted 48 hours after the cells (RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cell lines) are plated into 96-well plates on day 0 and exposed to oxaliplatin on day 1. Except for when adding oxaliplatin and during the final assay period, the plates are always incubated at 37 °C in 5% CO2 and 100% relative humidity. The assay started with 2–20 × 103 cells/50 nL/well plated on a slide. On the day of the assay, the cells in control wells must still be in the log phase of growth; the maximum absorbance for the untreated controls must fall between 1.0 and 1.5; and the cells must undergo more than two doublings during the drug exposure. These criteria are based on pilot studies. A concentration is made up of eight wells. Using an IBM PC-compatible computer as the interface, a Biotek Instruments model EL309 microplate reader is used to read the plates at 570–540 nm. The computer program DATALOG transfers the data and converts it into a LOTUS 1-2-3 format. The drug treated and control are compared to determine the survival fractions.
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C8H14N2O4PT
|
---|---|
Molecular Weight |
397.29
|
Exact Mass |
397.06
|
Elemental Analysis |
C, 24.19; H, 3.55; N, 7.05; O, 16.11; Pt, 49.10
|
CAS # |
61825-94-3
|
Appearance |
White solid powder
|
SMILES |
C1CC[C@H]([C@@H](C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]
|
InChi Key |
DRMCATBEKSVAPL-BNTLRKBRSA-N
|
InChi Code |
InChI=1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+2/t5-,6-;;/m1../s1
|
Chemical Name |
[(1R,2R)-2-azanidylcyclohexyl]azanide;oxalic acid;platinum(2+)
|
Synonyms |
L-OHP; diaminocyclohexane oxalatoplatinum; oxalatoplatin; oxalatoplatinum; US brand name: Eloxatin Foreign brand names: Dacotin; Dacplat; Eloxatine; Abbreviations: 1OHP; LOHP; Code names: JM83; RP54780; SR96669.
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.5171 mL | 12.5853 mL | 25.1705 mL | |
5 mM | 0.5034 mL | 2.5171 mL | 5.0341 mL | |
10 mM | 0.2517 mL | 1.2585 mL | 2.5171 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT01061515 | Active Recruiting |
Drug: Bevacizumab Drug: Capecitabine |
Carcinoma | Washington University School of Medicine |
May 10, 2011 | Phase 1 |
NCT03451331 | Active Recruiting |
Drug: Oxaliplatin Drug: Carboplatin |
Metastatic Urothelial Cancer | Matthew Galsky | May 10, 2018 | Phase 2 |
NCT03153280 | Active Recruiting |
Drug: Lithium Drug: Oxaliplatin |
Colorectal Neoplasms Stomach Neoplasm |
Cancer Trials Ireland | January 13, 2022 | Phase 1 |
NCT03255434 | Active Recruiting |
Drug: Oxaliplatin Drug: Oxaliplatin LBM |
Stage III Colon Cancer | Institut du Cancer de Montpellier - Val d'Aurelle |
November 1, 2017 | Phase 2 |
NCT03567629 | Active Recruiting |
Drug: Irinotecan Drug: Oxaliplatin |
mCRC | Peking University | May 29, 2018 | Phase 2 |